Thank you to the following companies who have provided educational grants to make the SCCNG Study Day 2016 possible:
Servier is an international pharmaceutical company, with no shareholders, governed by a non‐profit Foundation and headquartered in France. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiology, oncology, metabolism, neuropsychiatry and rheumatology, as well as by its activities in high quality generic drugs. Being completely independent, the Group reinvests 25% of Servier’s products turnover in Research and Development, and all its profits in its growth.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
medac is an innovative German pharmaceutical company with a well- established reputation and experience in oncology, haematology and rheumatology. They are specialists offering a broad spectrum of products from standard cancer chemotherapy to niche speciality medicines. They provide high quality products and seek innovative solutions to therapeutic problems.
Merck Serono is the biopharmaceutical division of Merck, with a focus on transforming people’s lives for the better. They strive to bring breakthrough solutions to people living with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases.
Norgine Pharmaceuticals Ltd is committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses.Its core focus is on gastroenterology, hepatology, pain management, and incontinence.
The primary objective of Sirtex Medical is to research, develop, and commercialise effective treatments for liver cancer using novel small particle technology. Sirtex continuously improves upon its liver cancer treatments through a program of research and clinical studies carried out across the world.
Volition is a cancer diagnostics company established in 2010 with a proprietary immunoassay based epigenetic profiling technology – Nucleosomics®. Our aim is to revolutionize the way cancer is diagnosed using this unique combination of long-established ELISA diagnostic technology with cutting-edge nucleosome detection and analysis techniques.